Neoplasm malignant
RecruitingA study of PM54 and pembrolizumab in adults with advanced cancer
- Disease:Neoplasm malignant
- Substances:Pembrolizumab
France- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Pharma Mar S.A.
Rare diseases
Investigational molecules
Locations
Avenida De Los Reyes 1, Poligono Industrial La Mina, 28770, Spain
Pharma Mar S.A. focuses on advanced solid tumors and broader advanced malignancies, with studies spanning heavily pretreated adult patients and multiple tumor types. Its clinical program includes interest in selected advanced solid tumors and basket-style oncology development across refractory disease settings.
These oncology trials reflect sustained activity in difficult-to-treat solid tumor settings across multiple collaborating sites and countries.
Pharma Mar S.A. runs clinical trials in conditions such as Neoplasm malignant, Small cell lung cancer, Leiomyosarcoma metastatic, among others.
Clinical trials run by this sponsor – those enrolling participants first.
France
Spain
France
Austria
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.